Alector, Inc. cotiza a 2.08 USD y tiene una capitalización bursátil de $232M. En los últimos 12 meses ha facturado $14M con un margen de flujo de caja libre del -874.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta an…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.21 | $-0.21 | $-0.34 |
| Estimado | $-0.21 | $-0.23 | $-0.27 | $-0.36 |
| Sorpresa | — | +8.7% | +22.2% | +5.6% |
| Métrica | ALEC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -741.3% | -38.6% | -702.7% |
| Net Margin | -679.2% | -33.6% | -645.6% |
| FCF Margin | -874.7% | -13.9% | -860.8% |
| ROE | -466.3% | -40.4% | -425.9% |
| ROA | -48.7% | -32.0% | -16.7% |
| Current Ratio | 3.83 | 2.84 | +0.99 |
| Debt / Equity | 0.33 | 0.28 | +0.05 |